520 related articles for article (PubMed ID: 25656043)
1. Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants.
Sivolella S; De Biagi M; Brunello G; Berengo M; Pengo V
Odontology; 2015 Sep; 103(3):258-63. PubMed ID: 25656043
[TBL] [Abstract][Full Text] [Related]
2. Warfarin and Newer Agents: What the Oral Surgeon Needs to Know.
Steed MB; Swanson MT
Oral Maxillofac Surg Clin North Am; 2016 Nov; 28(4):515-521. PubMed ID: 27624772
[TBL] [Abstract][Full Text] [Related]
3. Direct oral anticoagulant drugs (DOAC).
Blum RA; Lindfield D
J Cataract Refract Surg; 2016 Jan; 42(1):171-2. PubMed ID: 26948793
[No Abstract] [Full Text] [Related]
4. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
5. Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study.
Cheung CL; Sing CW; Lau WCY; Li GHY; Lip GYH; Tan KCB; Cheung BMY; Chan EWY; Wong ICK
Cardiovasc Diabetol; 2021 Mar; 20(1):71. PubMed ID: 33766030
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
7. Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin
.
Adachi T; Hoshino H; Takagi M; Fujioka S;
Cerebrovasc Dis Extra; 2017; 7(1):62-71. PubMed ID: 28376486
[TBL] [Abstract][Full Text] [Related]
8. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
[TBL] [Abstract][Full Text] [Related]
9. [Monitoring options and reversal agents for oral anticoagulants].
Thorup SB; Husted SE; Vang ML
Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096568
[TBL] [Abstract][Full Text] [Related]
10. The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation.
Harel Z; McArthur E; Jeyakumar N; Sood MM; Garg AX; Silver SA; Dorian P; Blum D; Beaubien-Souligny W; Yan AT; Badve SV; Smyth B; Jun M; Jandoc R; Kitchlu A; Wald R
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1470-1479. PubMed ID: 34407990
[TBL] [Abstract][Full Text] [Related]
11. Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.
Eek AK; Øie E; Granas AG
Eur J Clin Pharmacol; 2018 Mar; 74(3):323-330. PubMed ID: 29149366
[TBL] [Abstract][Full Text] [Related]
12. New Oral Anticoagulants: What Prescribers Should Know; Differences and Similarities between Warfarin and "New Agents" (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) - Review of Indications, Contraindications and Safety of Use.
Petrasko M; Raizada A; Petraskova T
S D Med; 2016 Aug; 69(8):363-369. PubMed ID: 28806005
[No Abstract] [Full Text] [Related]
13. [Not Available].
Själander S; Själander A
Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512136
[No Abstract] [Full Text] [Related]
14. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
[TBL] [Abstract][Full Text] [Related]
15. Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
Alamneh EA; Chalmers L; Bereznicki LR
Am J Cardiovasc Drugs; 2016 Jun; 16(3):183-200. PubMed ID: 26862063
[TBL] [Abstract][Full Text] [Related]
16. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885
[TBL] [Abstract][Full Text] [Related]
17. Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon.
Tscholl V; Lsharaf AK; Lin T; Bellmann B; Nagel P; Lenz K; Landmesser U; Roser M; Rillig A
Clin Cardiol; 2017 Nov; 40(11):1095-1099. PubMed ID: 28846806
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data.
Terayama Y
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1171-1181. PubMed ID: 28169097
[TBL] [Abstract][Full Text] [Related]
19. Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?
Pham PN; Brown JD
BMC Cardiovasc Disord; 2019 Mar; 19(1):64. PubMed ID: 30890131
[TBL] [Abstract][Full Text] [Related]
20. An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery.
Johnston S
Int J Oral Maxillofac Surg; 2016 May; 45(5):618-30. PubMed ID: 26774397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
